Ask Dr. Durie - Doctors' Edition

CME / ABIM MOC
Ask Dr Durie – Doctors’ Edition: Proteasome Inhibitors in Multiple Myeloma
 
Authors: Brian Durie, MD; Shaji Kumar, MD; Thomas Martin, MD; Joseph Mikhael, MD; Saad Usmani, MD

CME / ABIM MOC Released: 1/25/2018     Valid for credit through: 1/25/2019

BEGIN ACTIVITY


Now available from Medscape are CME courses for health-care professionals authored by the following myeloma experts: Drs. Brian G.M. Durie, Shaji Kumar, Thomas Martin, Joseph Mikhael, and Saad Usmani. This special edition of the “Ask Dr. Durie” series has been created for doctors and covers “Proteasome Inhibitors in Multiple Myeloma.” Participants must complete all sections of these activities to receive credit. 

Contents of This CME Activity

All sections of this activity are required for credit.


Section 1. What Are Proteasome Inhibitors and How Are They Used to Treat Multiple Myeloma?
Join Dr Durie as he introduces how proteasome inhibitors are used in multiple myeloma.
Brian Durie, MD

   


Section 2. How Are Proteasome Inhibitors Used in Frontline Therapy?
Learn how proteasome inhibitors are incorporated into treatment for patients with newly diagnosed multiple myeloma.
Brian Durie, MD; Shaji Kumar, MD

   


Section 3. Does High-Risk Disease Impact Proteasome Inhibitor-Based Therapy Selection?
Learn how proteasome inhibitors are used for patients with high-risk disease.
Brian Durie, MD; Saad Z. Usmani, MD

   


Section 4. How Are Proteasome Inhibitors Used in the Relapsed Setting?
Learn what to consider when selecting therapy for patients with relapsed multiple myeloma.
Brian Durie, MD; Thomas Martin, MD

   


Section 5. What Are the Adverse Events Associated With Proteasome Inhibitors And How Are They Managed?
Learn how to manage proteasome inhibitor-related adverse events.
Brian Durie, MD; Joseph Mikhael, MD

   


Section 6. Program Highlights
Dr Durie summarizes key components for using proteasome inhibitors.
Brian Durie, MD